Founded at the Abramson Cancer Center at the University of Pennsylvania

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

JAMA Oncology | 2021

Lova Sun, MD; Miles Hsu, MD; Roger B. Cohen, MD; Corey J. Langer, MD; Ronac Mamtani, MD, MSCE; Charu Aggarwal, MD, MPH